Two National Guard members shot near White House
Investing.com -- Straumann refined its mid-term outlook at the Capital Markets Day, signaling a more measured but still constructive path for growth as it looks to consolidate its position across implantology, orthodontics and dental digital technologies.
The company now targets around 10% organic sales growth (OSG), compared with its previous goal of at least 10%, and expects core EBIT margins to expand by 40 to 50 basis points per year from 2026 to 2030. The earlier margin framework called for 25–30% at constant currency.
Jefferies analyst Julien Dormois said the refined targets are “bang in line with consensus expectations,” which sit at 8.5–10% for organic growth and 25% and 27.5% for full-year 2025 (FY25) and FY30 margins.
“We believe investors should welcome increased caution on OSG prospects, allowing the return of beat-and-raise,” Dormois wrote.
Management laid out a strategy built on strengthening Straumann’s competitive edge in innovation and digital workflows, aiming to make treatments more predictable, faster and more efficient.
According to Dormois, the company plans to leverage leading technologies to “continue to expand market share across all businesses and customer segments,” supported by a multi-brand approach in implantology, a redesigned orthodontics business built for scale, and “substantial prosthetic growth potential” enabled by new digital tools.
The updated financial plan includes a firmer focus on productivity. Straumann is targeting margin expansion driven by efficiency programs across the organization, as well as tighter management of capex and working capital.
These efforts are expected to lift free-cash-flow (FCF) conversion steadily through 2030, reinforcing the company’s push for stronger profitability while sustaining investments in innovation.
Dormois highlighted Straumann’s appeal as a global leader in dental implants with meaningful room for further penetration.
The analyst pointed to its “best-in-class mgmt, excellent execution and inroads into adjacent, high-growth segments,” but noted that the stock’s roughly 28-times 2026 earnings multiple remains below its 10-year average, which he attributed to the discount to uncertainty in China and a softer U.S. macro backdrop.